Filing Flows › Karyopharm Therapeutics (KPTI) › Q3 2025
Karyopharm Therapeutics (KPTI) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 3, 2025
Karyopharm Therapeutics (KPTI) reported revenue of $44.0M for the third quarter 2025 (Q3 2025), +14% from a year earlier and +16% from the quarter before. Operating margin was -34.6%, net loss $33.1M (75.2% of revenue).
Karyopharm Therapeutics, Q3 2025: revenue $44.0M (+14% year over year), operating margin -34.6%, net loss $33.1M, operating cash flow −$5.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $44.0M | +16% | +14% |
| Operating profit | −$15.2M | — | — |
| Net earnings | −$33.1M | — | — |
| Operating cash flow | −$5.9M | — | — |
What changed
Revenue was $44.0M in Q3 2025, up 14% year over year and up 16% from the previous quarter. Product was the largest line at 73% of revenue. License and Other added $2.7M year over year (up 30%), 52% of the total change.
Operating costs exceeded revenue by $15.2M, an operating margin of -34.6%. Total costs fell 9% while revenue rose 14%. The fastest-growing cost line was Other operating costs (+63%). The quarter ended with a net loss of $33.1M, narrower than the previous quarter's $37.3M loss. Net interest and other expense of $17.9M was the main reason.
Operating cash flow was −$5.9M. Non-cash charges added back $121K of depreciation and $2.8M of share-based compensation. Working capital and other items added $24.3M.
Questions
What was Karyopharm Therapeutics' revenue in the third quarter 2025?
Karyopharm Therapeutics (KPTI) reported revenue of $44.0M for the third quarter 2025 (Q3 2025), +14% from a year earlier and +16% from the quarter before.
Was Karyopharm Therapeutics profitable in the third quarter 2025?
Operating loss was $15.2M (-34.6% of revenue) and net loss $33.1M.